{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:03:51Z","timestamp":1777500231642,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.exer.2021.108439","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T19:25:10Z","timestamp":1610479510000},"page":"108439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Intravitreal melphalan hydrochloride vs propylene glycol-free melphalan for retinoblastoma vitreous seeds: Efficacy, toxicity and stability in rabbits models and patients"],"prefix":"10.1016","volume":"204","author":[{"given":"Carley M.","family":"Bogan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janene M.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie D.","family":"Doss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuankai K.","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheau-chiann","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelli L.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1424-4431","authenticated-orcid":false,"given":"Albert","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7405-308X","authenticated-orcid":false,"given":"Terry","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Abramson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine H.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra L.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9580-900X","authenticated-orcid":false,"given":"Ann","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony B.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.exer.2021.108439_bib1","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1001\/archopht.122.9.1316","article-title":"Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth group Vb retinoblastoma","volume":"122","author":"Abramson","year":"2004","journal-title":"Arch. Ophthalmol."},{"issue":"8","key":"10.1016\/j.exer.2021.108439_bib2","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.ophtha.2007.12.014","article-title":"A phase I\/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results","volume":"115","author":"Abramson","year":"2008","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.exer.2021.108439_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146582","article-title":"Intra-arterial chemotherapy (ophthalmic artery chemosurgery) for group D retinoblastoma","volume":"11","author":"Abramson","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.exer.2021.108439_bib4","series-title":"Research Triangle","article-title":"Alkeran [package insert]","year":"2007"},{"issue":"12","key":"10.1016\/j.exer.2021.108439_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26696","article-title":"Long-term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era","volume":"64","author":"Berry","year":"2017","journal-title":"Pediatr. Blood Canc."},{"issue":"12","key":"10.1016\/j.exer.2021.108439_bib6","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.ophtha.2017.05.034","article-title":"Not all seeds are created equal: seed classification is predictive of outcomes in retinoblastoma","volume":"124","author":"Berry","year":"2017","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.exer.2021.108439_bib7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000486098","article-title":"Integrated treatment during the intravitreal melphalan era: concurrent intravitreal melphalan and systemic chemoreduction","volume":"4","author":"Berry","year":"2018","journal-title":"Ocul Oncol Pathol"},{"issue":"4","key":"10.1016\/j.exer.2021.108439_bib8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000493687","article-title":"Posterior vitreous detachment and the associated risk of retinal toxicity with intravitreal melphalan treatment for retinoblastoma","volume":"5","author":"Berry","year":"2019","journal-title":"Ocul Oncol Pathol"},{"issue":"3","key":"10.1016\/j.exer.2021.108439_bib9","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1364\/BOE.9.001244","article-title":"Quantitative biometry of zebrafish retinal vasculature using optical coherence tomographic angiography","volume":"9","author":"Bozic","year":"2018","journal-title":"Biomed. Optic Express"},{"issue":"1","key":"10.1016\/j.exer.2021.108439_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10633-008-9164-3","article-title":"Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma","volume":"119","author":"Brodie","year":"2009","journal-title":"Doc. Ophthalmol."},{"issue":"1","key":"10.1016\/j.exer.2021.108439_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10633-012-9358-6","article-title":"Persistence of retinal function after intravitreal melphalan injection for retinoblastoma","volume":"126","author":"Brodie","year":"2013","journal-title":"Doc. Ophthalmol."},{"issue":"11","key":"10.1016\/j.exer.2021.108439_bib12","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaophthalmol.2014.2324","article-title":"Stability of melphalan solution for intravitreal injection for retinoblastoma","volume":"132","author":"Buitrago","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"10.1016\/j.exer.2021.108439_bib13","first-page":"288","article-title":"Pharmaceutical approval update","volume":"41","author":"Choy","year":"2016","journal-title":"P T"},{"issue":"1","key":"10.1016\/j.exer.2021.108439_bib14","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1167\/iovs.17-22302","article-title":"Pharmacokinetics, tissue localization, toxicity, and treatment efficacy in the first small animal (rabbit) model of intra-arterial chemotherapy for retinoblastoma","volume":"59","author":"Daniels","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.exer.2021.108439_bib15","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1167\/iovs.18-25346","article-title":"Rabbit model of intra-arterial chemotherapy toxicity demonstrates retinopathy and vasculopathy related to drug and dose, not procedure or approach","volume":"60","author":"Daniels","year":"2019","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.exer.2021.108439_bib17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40268-015-0098-4","article-title":"Stability of melphalan in 0.9% sodium chloride solutions prepared in polyvinyl chloride bags for intravenous injection","volume":"15","author":"Desmaris","year":"2015","journal-title":"Drugs R"},{"issue":"9","key":"10.1016\/j.exer.2021.108439_bib18","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.ophtha.2014.03.028","article-title":"Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study","volume":"121","author":"Francis","year":"2014","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.exer.2021.108439_bib19","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.ophtha.2015.01.017","article-title":"The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan","volume":"122","author":"Francis","year":"2015","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.exer.2021.108439_bib20","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.ophtha.2017.04.010","article-title":"Retinoblastoma vitreous seed clouds (class 3): a comparison of treatment with ophthalmic artery chemosurgery with or without intravitreous and periocular chemotherapy","volume":"124","author":"Francis","year":"2017","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.exer.2021.108439_bib21","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ophtha.2016.12.015","article-title":"Efficacy and toxicity of intravitreous chemotherapy for retinoblastoma: four-year experience","volume":"124","author":"Francis","year":"2017","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.exer.2021.108439_bib22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10633-004-3924-5","article-title":"Standardized full-field electroretinography in rabbits","volume":"109","author":"Gjorloff","year":"2004","journal-title":"Doc. Ophthalmol."},{"issue":"7","key":"10.1016\/j.exer.2021.108439_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235016","article-title":"Comparison of efficacy and toxicity of intravitreal melphalan formulations for retinoblastoma","volume":"15","author":"Hsieh","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.exer.2021.108439_bib24","series-title":"TOXICITY and EFFICACY of INTRAVITREAL MELPHALAN for RETINOBLASTOMA: 25 Microg versus 30 Microg","author":"Liao","year":"2020"},{"issue":"1","key":"10.1016\/j.exer.2021.108439_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10633-013-9416-8","article-title":"Non-selectivity of ERG reductions in eyes treated for retinoblastoma","volume":"128","author":"Liu","year":"2014","journal-title":"Doc. Ophthalmol."},{"issue":"9","key":"10.1016\/j.exer.2021.108439_bib26","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1021\/js9704442","article-title":"Comparison of the effects of potential parenteral vehicles for poorly water soluble anticancer drugs (organic cosolvents and cyclodextrin solutions) on cultured endothelial cells (HUV-EC)","volume":"87","author":"Medlicott","year":"1998","journal-title":"J. Pharmaceut. Sci."},{"issue":"4","key":"10.1016\/j.exer.2021.108439_bib27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/13816810.2014.973045","article-title":"Classification and management of seeds in retinoblastoma. Ellsworth lecture ghent august 24th 2013","volume":"35","author":"Munier","year":"2014","journal-title":"Ophthalmic Genet."},{"issue":"8","key":"10.1016\/j.exer.2021.108439_bib28","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/bjophthalmol-2011-301016","article-title":"Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track","volume":"96","author":"Munier","year":"2012","journal-title":"Br. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.exer.2021.108439_bib29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.sjopt.2013.06.003","article-title":"Intravitreal chemotherapy for vitreous seeding in retinoblastoma: recent advances and perspectives","volume":"27","author":"Munier","year":"2013","journal-title":"Saudi J Ophthalmol"},{"issue":"5","key":"10.1016\/j.exer.2021.108439_bib30","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0002-9394(02)01348-X","article-title":"Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation","volume":"133","author":"Shields","year":"2002","journal-title":"Am. J. Ophthalmol."},{"issue":"12","key":"10.1016\/j.exer.2021.108439_bib31","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1016\/j.ophtha.2006.06.018","article-title":"The International Classification of Retinoblastoma predicts chemoreduction success","volume":"113","author":"Shields","year":"2006","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.exer.2021.108439_bib32","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/IAE.0000000000000903","article-title":"Intravitreous chemotherapy for active vitreous seeding from retinoblastoma: outcomes after 192 consecutive injections. The 2015 howard naquin lecture","volume":"36","author":"Shields","year":"2016","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.exer.2021.108439_bib33","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1080\/10837450.2016.1265557","article-title":"Solution stability of Captisol-stabilized melphalan (Evomela) versus Propylene glycol-based melphalan hydrochloride injection","volume":"23","author":"Singh","year":"2018","journal-title":"Pharmaceut. Dev. Technol."},{"issue":"7","key":"10.1016\/j.exer.2021.108439_bib34","first-page":"1380","article-title":"Stability of melphalan in infusion fluids","volume":"41","author":"Tabibi","year":"1984","journal-title":"Am. J. Hosp. Pharm."},{"issue":"7","key":"10.1016\/j.exer.2021.108439_bib35","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1177\/1078155218804042","article-title":"Evaluating the adverse effects of melphalan formulations","volume":"25","author":"Xiang","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"1","key":"10.1016\/j.exer.2021.108439_bib36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12886-019-1059-4","article-title":"Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients","volume":"19","author":"Xue","year":"2019","journal-title":"BMC Ophthalmol."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448352100004X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448352100004X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:11:32Z","timestamp":1757999492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448352100004X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":35,"alternative-id":["S001448352100004X"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2021.108439","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravitreal melphalan hydrochloride vs propylene glycol-free melphalan for retinoblastoma vitreous seeds: Efficacy, toxicity and stability in rabbits models and patients","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2021.108439","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108439"}}